(IRTC) iRhythm Technologies - Ratings and Ratios

iRhythm Technologies, Inc. (NASDAQ: IRTC) is a digital healthcare company specializing in the development and commercialization of innovative, device-based solutions for ambulatory cardiac monitoring. The companys primary focus is on improving the diagnosis and management of arrhythmias through advanced ECG monitoring systems. Its flagship product, the Zio family of devices, includes the Zio Monitor System, Zio XT System, and Zio AT System, all of which are prescription-only, remote ECG monitoring solutions. These systems utilize proprietary algorithms and a cloud-based platform to capture and analyze cardiac data, enabling continuous monitoring for up to 14 days. The Zio ECG Utilization Software System further enhances the analysis of ECG data, providing actionable insights for healthcare providers. The company has also partnered with Verily Life Sciences and Verity Ireland Limited to co-develop next-generation solutions for atrial fibrillation detection and monitoring. iRhythm Technologies, Inc. was founded in 2006 and is headquartered in San Francisco, California.

The companys Zio AT System integrates a wireless gateway, ensuring seamless connectivity between the wearable patch and the ZEUS System, while the Zio XT System offers advanced features for extended monitoring. These solutions are designed to address the growing demand for accurate and efficient arrhythmia diagnosis, reducing the need for in-person consultations and enabling earlier intervention. iRhythms technology has been widely adopted in the U.S. healthcare system, with a strong focus on improving patient outcomes and reducing healthcare costs associated with cardiac monitoring. The company continues to innovate, expanding its portfolio to address unmet needs in cardiac care.